PAM
AIM

Panagora Asset Management’s AIM ImmunoTech AIM Stock Holding History

Panagora Asset Management’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-6
Closed -$14K – 2772
2017
Q1 		$14K Buy
6
+3
+100% +$7.67K ﹤0.01% 2241
2016
Q4 		$8K Hold
3
– – ﹤0.01% 2299
2016
Q3 		$14K Buy
+3
New +$21.1K ﹤0.01% 2318

Other funds holding AIM

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
OAM
Occidental Asset Management Burlingame, California $844M AUM 20.95% 1-Year Est. Return

Panagora Asset Management's AIM Position: Q2 2017 in Review

Panagora Asset Management sold out of AIM ImmunoTech (AIM) in Q2 2017, closing a stake of 6 shares — an estimated $14K sold.

Panagora Asset Management first reported a position in AIM in Q3 2016 and held it in 3 quarters. The position peaked at $14K in Q1 2017. 13 funds tracked by Wall St. Rank hold AIM as of Q2 2017.

  • Panagora Asset Management reported no remaining AIM ImmunoTech position as of Q2 2017 after selling out during the quarter.
  • Panagora Asset Management sold 6 AIM ImmunoTech shares in Q2 2017, an estimated $14K.
  • Panagora Asset Management first reported a position in AIM ImmunoTech in Q3 2016 and held it in 3 quarters.
  • Panagora Asset Management's AIM ImmunoTech position peaked at $14K in Q1 2017.
  • 13 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2017.

Based on Panagora Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.